Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director comp.
EQRx, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
08/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/08/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Termination of a Material Definitive Agreement, Cost Associated with Exit or Disposal Activities  Interactive...
08/01/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/01/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/01/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/01/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/01/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/01/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/01/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/01/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/01/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/01/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/01/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/01/2023 8-K Quarterly results
08/01/2023 425 Form 425 - Prospectuses and communications, business combinations:
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
Docs: "EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results"
03/13/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/06/2023 EFFECT Form EFFECT - Notice of Effectiveness:
03/06/2023 EFFECT Form EFFECT - Notice of Effectiveness:
02/23/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
02/23/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
02/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/23/2023 10-K Annual Report for the period ended December 31, 2022
02/23/2023 8-K Quarterly results
Docs: "EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress"
02/22/2023 4/A Abernethy Amy (Director) has filed a Form 4 on EQRx, Inc.
Txns: Granted options to buy @ $0
02/22/2023 4/A Abernethy Amy (Director) has filed a Form 4 on EQRx, Inc.
Txns: Granted 389,223 options to buy @ $3.03, valued at $1.2M
02/09/2023 SC 13G VANGUARD GROUP INC reports a 5.3% stake in EQRx Inc.
01/18/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
01/11/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "41st ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy